JOP20230065A1 - بولي ببتيدات لوكوسيدين a وb مغايرة من نوع المكورات العنقودية الذهبية وتركيبات لقاح - Google Patents

بولي ببتيدات لوكوسيدين a وb مغايرة من نوع المكورات العنقودية الذهبية وتركيبات لقاح

Info

Publication number
JOP20230065A1
JOP20230065A1 JOJO/P/2023/0065A JOP20230065A JOP20230065A1 JO P20230065 A1 JOP20230065 A1 JO P20230065A1 JO P20230065 A JOP20230065 A JO P20230065A JO P20230065 A1 JOP20230065 A1 JO P20230065A1
Authority
JO
Jordan
Prior art keywords
polypeptides
staphylococcus aureus
vaccine formulations
leucocidin
heterozygous
Prior art date
Application number
JOJO/P/2023/0065A
Other languages
Arabic (ar)
English (en)
Inventor
Peter T Buckley
Victor J Torres
Jeroen Geurtsen
Sandeep Somani
Sergey Konstantinov
Jinquan Luo
Brian Morrow
Original Assignee
Janssen Pharmaceuticals Inc
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Univ New York filed Critical Janssen Pharmaceuticals Inc
Publication of JOP20230065A1 publication Critical patent/JOP20230065A1/ar

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/085Staphylococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JOJO/P/2023/0065A 2020-09-28 2023-03-28 بولي ببتيدات لوكوسيدين a وb مغايرة من نوع المكورات العنقودية الذهبية وتركيبات لقاح JOP20230065A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063084273P 2020-09-28 2020-09-28
PCT/US2021/052418 WO2022067255A2 (en) 2020-09-28 2021-09-28 Variant staphylococcus aureus luka and lukb polypeptides and vaccine compositions

Publications (1)

Publication Number Publication Date
JOP20230065A1 true JOP20230065A1 (ar) 2023-03-28

Family

ID=80846955

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2023/0065A JOP20230065A1 (ar) 2020-09-28 2023-03-28 بولي ببتيدات لوكوسيدين a وb مغايرة من نوع المكورات العنقودية الذهبية وتركيبات لقاح

Country Status (15)

Country Link
US (1) US20240050546A1 (https=)
EP (1) EP4216982A4 (https=)
JP (1) JP2023544300A (https=)
KR (1) KR20230091911A (https=)
CN (1) CN116670158A (https=)
AR (1) AR123635A1 (https=)
AU (1) AU2021350860A1 (https=)
CA (1) CA3195895A1 (https=)
CL (1) CL2023000884A1 (https=)
CO (1) CO2023004198A2 (https=)
IL (1) IL301406A (https=)
JO (1) JOP20230065A1 (https=)
MX (1) MX2023003581A (https=)
NZ (1) NZ798451A (https=)
WO (1) WO2022067255A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3215751A1 (en) * 2021-04-02 2022-10-06 Janssen Pharmaceuticals, Inc. Staphylococcus aureus vaccine compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340522C (en) * 1987-03-10 1999-05-04 Heinz Dobeli Fusion proteins containing neighbouring histidines for improved purification
SE0102327D0 (sv) * 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
EP4015523A1 (en) * 2010-05-05 2022-06-22 New York University Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof
RU2016110800A (ru) * 2013-09-25 2017-10-30 Пронутриа Биосайенсис, Инк. Составы и композиции для поддержания и увеличения мышечной массы, силы и результативности, и способы их производства и использования
EP3464349A4 (en) * 2016-05-23 2020-08-26 New York University COMPOSITIONS AND METHODS ASSOCIATED WITH ANTIBODIES TARGETING STAPHYLOCCAL LEUCOTOXINS
EP3638286A4 (en) * 2017-06-13 2021-03-10 Integrated Biotherapeutic Vaccines, Inc. IMMUNOGENIC COMPOSITIONS CONTAINING POLYPEPTIDES DERIVED FROM LEUCOCIDINS LUKA AND LUKB OF STAPHYLOCOCCUS AUREUS
CA3215751A1 (en) * 2021-04-02 2022-10-06 Janssen Pharmaceuticals, Inc. Staphylococcus aureus vaccine compositions

Also Published As

Publication number Publication date
US20240050546A1 (en) 2024-02-15
CL2023000884A1 (es) 2023-09-29
IL301406A (en) 2023-05-01
JP2023544300A (ja) 2023-10-23
AR123635A1 (es) 2022-12-28
EP4216982A4 (en) 2025-03-19
WO2022067255A2 (en) 2022-03-31
CN116670158A (zh) 2023-08-29
CA3195895A1 (en) 2022-03-31
AU2021350860A1 (en) 2023-05-04
EP4216982A2 (en) 2023-08-02
KR20230091911A (ko) 2023-06-23
CO2023004198A2 (es) 2023-07-31
MX2023003581A (es) 2023-06-21
WO2022067255A3 (en) 2022-04-28
NZ798451A (en) 2024-11-29

Similar Documents

Publication Publication Date Title
CY1125827T1 (el) Συνθεσεις μικτων αλλεργιογονων και μεθοδοι χρησης αυτων
MX2025012429A (es) Composiciones y metodos para tratar el deterioro auditivo no asociado con la edad en un sujeto humano
EP4219724A3 (en) Compositions and methods for treating non-age-associated hearing impairment in a human subject
MX389758B (es) Ratones con genes insertados de sirpa-il15 humanizadas y métodos para usarlos
AR105028A1 (es) Control de intensidad subjetiva para interacción del usuario en sistemas de codificación de audio
AR102284A1 (es) Polipéptidos insecticidas que tienen un espectro de actividad mejorado y usos de estos
MX381015B (es) Composiciones y métodos para controlar plagas vegetales.
UY38889A (es) Inmunocitoquina que comprende un complejo de proteína heterodimérico basado en il-15/il-15r¿ y su uso
MX2018000170A (es) Composiciones y metodos para controlar plagas de plantas.
CY1123530T1 (el) Συνθεση ακαρεων και η χρηση της ως βιολογικος παραγοντας ελεγχου
JOP20220204B1 (ar) الأجسام المضادة لـ cd19 البشرية
CY1124640T1 (el) Μια meθοδος αντιμετωπισης μυκητιασικων μολυνσεων
IN2015DN03185A (https=)
CL2019001778A1 (es) Composiciones y métodos para controlar plagas de plantas.
MX2018008805A (es) Proteinas anti-microbianas.
AR100923A1 (es) Proteínas insecticidas vegetativas útiles para controlar plagas de insectos
JOP20230065A1 (ar) بولي ببتيدات لوكوسيدين a وb مغايرة من نوع المكورات العنقودية الذهبية وتركيبات لقاح
MX386095B (es) Metodos para tratar semillas con una composicion acuosa y semillas tratadas con la misma.
EP3843761A4 (en) Chimeric oncolytic herpesvirus that stimulate an antitumor immune response
MX2020007329A (es) Proteínas insecticidas quiméricas.
UY36134A (es) Mezclas que comprenden una cepa bacillus y un plaguicida
MX2017003657A (es) Composicion pesticida.
RU2013109820A (ru) Способ повышения содержания гумуса почвы с применением штаммов клубеньковых бактерий якутский № 2 люцерны
SE1530146A1 (en) Control Apparatus and Vehicle provided with Location Data ofStumps of Harvested Trees
DE202014007570U1 (de) Iris-Sofi-Quandtolinos Gingo-Bärlauchhonig und -wein